Concepedia

Ying‐Ming Jou

YJ

Statistics

Publications

12

Citations

907

H-Index

12

Active since

2013

Affiliations

Bristol-Myers Squibb (United States)(Current)

Dana-Farber Cancer Institute

AbbVie (United States)

University Medical Center Hamburg-Eppendorf

Azienda Ospedaliero-Universitaria di Modena

Ying‐Ming Jou is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and cancer immunotherapy.

Publications per year

2013–2022

12

Publications

12

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié et al. · Blood · 2016 · 235 citations · Full text

, , +12

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Meletios Α. Dimopoulos, Sagar Lonial, Darrell White et al. · Blood Cancer Journal · 2020 · 153 citations · Full text

, , +15

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

John Nemunaitis, Karen Small, Paul T. Kirschmeier et al. · Journal of Translational Medicine · 2013 · 129 citations · Full text

, , +17

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki et al. · Journal of Clinical Oncology · 2022 · 110 citations · Full text

, , +15

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Joe Stephenson, John Nemunaitis, Anil A. Joy et al. · Lung Cancer · 2013 · 100 citations

, , +14

1–5 of 12